Discovering that calcitonin-related peptide (CGRP) plays a key role in the complex
pathophysiology of migraine has allowed us to make great strides in the development of …

Up to 20 years ago, ergotamine and dihydroergotamine (DHE) were the only specific
antimigraine drugs [1]. Then subcutaneous sumatriptan 6 mg was introduced in 1991 [2, 3] …

Background: There is evidence that headache response rates may be higher if triptans are
used early when a migraine attack is still mild, as compared to when it is treated after pain …

The primary endpoint traditionally measured in clinical trials of triptans for acute migraine
therapy has been 2-hour pain relief, a decrease in pain intensity from moderate/severe to …

Migraine affects about one billion people worldwide yearly and is one of the most common
neurologic illnesses, with a high prevalence and morbidity, particularly among young adults …

Migraine treatment has evolved into the scientific arena, but it seems still controversial
whether migraine is primarily a vascular or a neurological dysfunction. Irrespective of this …

Migraine is a neurovascular disorder characterized by recurrent unilateral headaches
accompanied by nausea, vomiting, photophobia and phonophobia. Current theories …

Objective.—To evaluate the efficacy and tolerability of treatment with a combination of
sumatriptan 50 mg (encapsulated) and naproxen sodium 500 mg administered concurrently …

Opinion Statement The conceptual shift of our understanding of migraine from a vascular
disorder to a brain disorder has dramatically altered the approach to the development of …

The biological profile of naratriptan (N‐methyl‐3‐(1‐methyl‐4‐piperidinyl)‐1H‐indole‐5‐
ethane‐sulphona‐mide), a novel 5HT1B/1D receptor agonist, was investigated in a variety …